ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

University of Pittsburgh Medical Center to spend big on drug development

by Megha Satyanarayana
January 16, 2020 | APPEARED IN VOLUME 98, ISSUE 3

09803-buscon16-upmc.jpg
Credit: UPMC

UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center, says it will spend $1 billion over the next 4 years to develop new drugs, diagnostics, and medical devices. The investment includes a previously announced $200 million to support an immunotherapy venture with the University of Pittsburgh. In the past 2 years, UPMC Enterprises has launched five companies and invested in another, Werewolf Therapeutics. In addition to immunotherapy, it will target respiratory disease and neuroinflammation, among other illnesses.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment